Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $82 | $27 | $62 | $148 |
| % Growth | 204.8% | -56.8% | -57.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $82 | $27 | $62 | $148 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $103 | $89 | $79 | $67 |
| G&A Expenses | $31 | $29 | $29 | $28 |
| SG&A Expenses | $31 | $29 | $29 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $134 | $118 | $107 | $95 |
| Operating Income | -$52 | -$91 | -$45 | $53 |
| % Margin | -63.7% | -338.4% | -72.4% | 35.7% |
| Other Income/Exp. Net | $1 | $0 | $1 | $4 |
| Pre-Tax Income | -$51 | -$91 | -$44 | $57 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51 | -$91 | -$44 | $57 |
| % Margin | -62.1% | -337.7% | -70.3% | 38.4% |
| EPS | -0.99 | -1.82 | -1.24 | 1.72 |
| % Growth | 45.6% | -46.8% | -172.1% | – |
| EPS Diluted | -0.99 | -1.82 | -1.24 | 1.66 |
| Weighted Avg Shares Out | 52 | 50 | 35 | 33 |
| Weighted Avg Shares Out Dil | 52 | 50 | 35 | 34 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $3 | $3 | $4 |
| EBITDA | -$50 | -$91 | -$45 | $53 |
| % Margin | -61.2% | -338.4% | -72.4% | 35.7% |